Coronado Biosciences Announces Independent Data Monitoring Committee Recommends Discontinuing Falk Phase 2 Trial of TSO in Crohn's Disease
November 07, 2013 at 06:38 AM EST
Coronado Biosciences (NASDAQ: CNDO ) today announced that it has been informed by Dr. Falk Pharma GmbH (Falk), its development partner, that an Independent Data Monitoring Committee (IDMC) has conducted a second interim analysis of clinical data from approximately 240 patients who have completed 12 weeks of treatment in